NCT07094048
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- Santé Québec Chaudière-Appalaches Lévis, Quebec, Canada
- Centre Intégré de Cancérologie Québec, Quebec, Canada
Clinical trial condition
Relapsed Multiple Myeloma
Explore clinical trials studying Relapsed Multiple Myeloma. Study availability and eligibility vary by location and protocol.
26 public trials
5 recruiting studies
Relapsed Multiple Myeloma trial results
NCT06433947
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- Banner MD Anderson Gilbert, Arizona, United States
- UC San Diego Moores Cancer Center La Jolla, California, United States
- Stanford Cancer Institute Stanford, California, United States
- Emory Winchip Cancer Center Atlanta, Georgia, United States
NCT06348108
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- University of Calfornia, San Francisco San Francisco, California, United States
NCT05896228
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- University of Miami Miami, Florida, United States
NCT06119685
- Conditions
- Blood Cancer, Blood Protein Disorders, Cardiovascular Diseases, +23 more
- Locations
-
- Valkyrie Clinical Trials Los Angeles, California, United States
- Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center Lake Mary, Florida, United States
- Emory University Hospital Atlanta, Georgia, United States
- University of Minnesota Minneapolis, Minnesota, United States
Not Yet Recruiting
INfections in Patients Treated With CAR-T
NCT07713511
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Blood Protein Disorders, Bloodstream Infections, +29 more
- Locations
-
- IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna, Italy
NCT04083534
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- Regeneron Study Site Indianapolis, Indiana, United States
- Regeneron Study Site Ann Arbor, Michigan, United States
- Regeneron Study Site Rochester, Minnesota, United States
- Regeneron Study Site New York, United States
Completed
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
NCT05228470
- Conditions
- BCMA, BCMA-CD3 Bispecific, Bispecific, +23 more
- Locations
-
- Fujian Medical University Union Hospital Fuzhou, Fujian, China
- Guangdong Provincial People's Hospital Guangzhou, Guangdong, China
- Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
NCT02722668
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia, +74 more
- Locations
-
- Masonic Cancer Center at University of Minnesota Minneapolis, Minnesota, United States
NCT03158688
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- Lynn Cancer Center Boca Raton Regional Hospital, Lynn Cancer Institute Boca Raton, Florida, United States
- Emory University Winship Cancer Institute Atlanta, Georgia, United States
- University of Chicago Medical Center - Multiple Myeloma Research Consortium Chicago, Illinois, United States
- Fort Wayne Medical Oncology and Hematology Fort Wayne, Indiana, United States